The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy
Abstract
OBJECTIVE: To determine the prevalence, course and risk factors for hyperlactatemia in HIV-infected patients. DESIGN: A prospective, longitudinal study of venous lactate concentrations over an 18-month period in 349 participants of the Western Australian HIV Cohort Study. RESULTS: In 516 patient-years of observation, two patients experienced severe fulminant lactic acidosis (lactate > 5 mmol/l) and hepatic steatosis attributable to nucleoside analogue reverse transcriptase inhibitors (NRTI). A further five patients with lesser elevations of lactate (2.8-4.1 mmol/l) but with symptoms of nausea or abdominal discomfort and evidence of hepatic steatosis had NRTI therapy revised, with relief of symptoms and a fall in lactate levels. Most remaining patients on highly active antiretroviral therapy (HAART) had mild, chronic, asymptomatic hyperlactatemia, with mean lactate level between 1.5 mmol/l and 3.5 mmol/l most commonly. Longitudinal data was analysed in a non-linear mixed effects growth model which indicated that average lactate levels rose after the start of HAART but tended to stabilise at low-grade elevation, with an average 0.23 mmol/l greater long term level in stavudine users compared with zidovudine users (p < 0.01). A multiple linear regression model showed that the association between stavudine and higher lactate level was not confounded by longer duration of total NRTI exposure. Risk of hyperlactatemia was not significantly associated with use of other NRTIs, protease inhibitors, non-nucleoside analogue reverse transcriptase inhibitors or multiple immunological and virological factors in multivariate analyses. CONCLUSIONS: Chronic, compensated, asymptomatic hyperlactatemia is common in patients taking HAART. Decompensated, life-threatening lactic acidosis/hepatic steatosis is rare. Treatment with stavudine appears to be the predominant risk factor for development of chronic hyperlactatemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brinkman, K., Smeitink, J. A., Romijn, J. A., & Reiss, P. (1999) · The Lancet · doi:10.1016/s0140-6736(99)06102-4 · Cited by 866
Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway
Brinkman, K., ter Hofstede, H. J. M., Burger, D. M., Smeitink, J. A. M., & Koopmans, P. P. (1998) · AIDS · doi:10.1097/00002030-199814000-00004 · Cited by 847
Carr, A., Miller, J., Law, M., & Cooper, D. A. (2000) · AIDS · doi:10.1097/00002030-200002180-00001 · Cited by 630
Saint-Marc, T., Partisani, M., Poizot-Martin, I., Bruno, F., Rouviere, O., Lang, J.-M., Gastaut, J.-A., & Touraine, J.-L. (1999) · AIDS · doi:10.1097/00002030-199909100-00009 · Cited by 581
Mallal, S. A., John, M., Moore, C. B., James, I. R., & McKinnon, E. J. (2000) · AIDS · doi:10.1097/00002030-200007070-00002 · Cited by 510
Self-citationRedistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
Gervasoni, C., Ridolfo, A. L., Trifirò, G., Santambrogio, S., Norbiato, G., Musicco, M., Clerici, M., Galli, M., & Moroni, M. (1999) · Aids · doi:10.1097/00002030-199903110-00004 · Cited by 298
Madias, N. E. (1986) · Kidney International · doi:10.1038/ki.1986.62 · Cited by 233
Lonergan, J. T., Behling, C., Pfander, H., Hassanein, T. I., & Mathews, W. C. (2000) · Clinical Infectious Diseases · doi:10.1086/313912 · Cited by 208
Kakuda, T. N., Brundage, R. C., Anderson, P. L., & Fletcher, C. V. (1999) · AIDS · doi:10.1097/00002030-199911120-00019 · Cited by 144
Sundar, K., Suarez, M., Banogon, P. E., & Shapiro, J. M. (1997) · Critical Care Medicine · doi:10.1097/00003246-199708000-00034 · Cited by 130
Cited by
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Changes in Mitochondrial DNA as a Marker of Nucleoside Toxicity in HIV-Infected Patients
Côté, H. C. F., Brumme, Z. L., Craib, K. J. P., Alexander, C. S., Wynhoven, B., Ting, L., Wong, H., Harris, M., Harrigan, P. R., O'Shaughnessy, M. V., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012035 · Cited by 573
Dybul, M., Fauci, A. S., Bartlett, J. G., Kaplan, J. E., & Pau, A. K. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-5_part_2-200209031-00001 · Cited by 482
Schambelan, M., Benson, C. A., Carr, A., Currier, J. S., Dubé, M. P., Gerber, J. G., Grinspoon, S. K., Grunfeld, C., Kotler, D. P., Mulligan, K., et al. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200211010-00001 · Cited by 379
A Review of the Toxicity of HIV Medications
Margolis, A. M., Heverling, H., Pham, P. A., & Stolbach, A. (2014) · Journal of Medical Toxicology · doi:10.1007/s13181-013-0325-8 · Cited by 348
Metadata
- Authors
- John, M., Moore, C. B., James, I. R., Nolan, D., Upton, R. P., McKinnon, E. J., & Mallal, S. A.
- Venue
- AIDS
- Published
- 2001-04
- Volume
- 15
- Issue
- 6
- Pages
- 717-723
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2085653450
- Cited by
- 264
- References
- 14
- FWCI
- 31.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. https://app.cochat.ai/papers/10.1097/00002030-200104130-00007
- The paper
- John, M., Moore, C. B., James, I. R., Nolan, D., Upton, R. P., McKinnon, E. J., & Mallal, S. A. (2001). Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS. https://doi.org/10.1097/00002030-200104130-00007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.